1Yip R G,Wolfe M M.GIP biology and fat metabolism[J].Life Sci.,2000,66(2):91-103. 被引量：1
2Trumper A,Trümper K,Trusheim H,et al.Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling[J].Mol Endocrinol,2001,15(9):1559-1570. 被引量：1
4Aschner P,Kipnes M S,Lunceford J K,et al.Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control inpatients with type 2 diabetes[J].Diabetes Care,2006,29(12):2632-2637. 被引量：1
5Raz I,Hanefeld M,Xu L,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus[J].Diabetologia,2006,49(11):2564-2571. 被引量：1
6Mohan V,Yang W,Son H Y,et al.Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China,India,and Korea[J].Diabetes Res Clin Pract,2009,83(1):106-116. 被引量：1
7Scherbaum W A,Schweizer A,Mari A,et al.Efficacy and tolerability of vildagliptin in drug nave patients with type 2 diabetes and mild hyperglycaemia[J].Diabetes Obes Metab,2008,10(8):675-682. 被引量：1
8Rosenstock J,Foley J E,Rendell M,et al.Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones,islet function,and postprandial glycemia in subjects with impaired glucose tolerance[J].Diabetes Care,2008,31(1):30-35. 被引量：1
9Rosenstock J,Sankoh S,List J F.Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes[J].Diabetes Obesity and Metabolism,2008,10(5):376-386. 被引量：1
10Rosenstock J,Aguilar-Salinas C,Klein E,et al.Effect of saxagliptin monotherapy in treatment-nave patients with type 2 diabetes[J].Curr Med Res Opin,2009,25(10):2401-2411. 被引量：1
二级参考文献15
1Y.-L. He,R. Sabo,J. Campestrini,Y. Wang,M. Ligueros-Saylan,K. C. Lasseter,S. C. Dilzer,D. Howard,W. P. Dole.The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin[J].European Journal of Clinical Pharmacology.2007(7) 被引量：1
2V. Fonseca,A. Schweizer,D. Albrecht,M. A. Baron,I. Chang,S. Dejager.Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes[J].Diabetologia.2007(6) 被引量：1
3N. Matikainen,S. M?ntt?ri,A. Schweizer,A. Ulvestad,D. Mills,B. E. Dunning,J. E. Foley,M.-R. Taskinen.Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes[J].Diabetologia.2006(9) 被引量：1
4Catherine A. Abbott,Geoffrey W. McCaughan,Elizabeth Baker,Grant R. Sutherland.Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene[J].Immunogenetics.1994(5) 被引量：1
5André Wettergren MD,Birgit Schjoldager MD,Poul Erik Mortensen MD,John Myhre MD,John Christiansen MD,Dr. Jens Juul Holst MD.Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man[J].Digestive Diseases and Sciences.1993(4) 被引量：1
6Ahrén B,Simonsson E,Larsson H,Landin-Olsson M,Torgeirsson H,Jansson PA.Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes[].Diabetes Care.2002 被引量：1
7Pratley RE,,Jauffret-Kamel S,Galbreath E,Holmes D.Twelveweek monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes[].Hormone and Metabolic Research.2006 被引量：1
8Raz I,Chen Y,Wu M,Hussain S,Kaufman KD,Amatruda JM.Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes[].Current Medical Research and Opinion.2008 被引量：1
9Lauster CD,McKaveney TP,Muench SV.Vildagliptin: a novel oral therapy for type 2 diabetes mellitus[].American Journal of Health System Pharmacy.2007 被引量：1
10Choy M,Lam S.Sitagliptin: a novel drug for the treatment of type 2 diabetes[].Cardiology Review.2007 被引量：1
6Ginter E, Simko V. Diabetes type 2 pandemic in 21st century [J]. BratislLekListy, 2010, 111(3): 134-137. 被引量：1
7Simon D. Epidemiologieal features of type 2 diabetes[J]. Rev Prat, 2010, 60(4): 469-473. 被引量：1
8Moore KB, Saudek CD. Therapeutic potential of dipeptidyl peptidase IV inhibitor in patients with diabetes mellitus[J]. Am J Ther, 2008, 15(5) : 484-491. 被引量：1
